(50 min interview with Bateman)
“Emerge Australia Podcast Series, 2/22/24: ‘
Ep. 20 – Dr Lucinda Bateman’
“I think things are moving forward and faster than ever before, but it takes time and it takes a critical mass of people engaged, but I do believe we're making progress”
‘We have a long way to go in understanding the core treatments..but the entire COVID pandemic has opened up a whole new avenue..new level of interest from clinicians & scientists..”
“I have a strong belief in the hypothesis that there's a role played by viruses and maybe other infections and the presence of that DNA or RNA and also the potential for reactivation”
“And then there's a tight connection with some kind of a chronic immune and inflammatory process that may feed back and forth. I also feel fairly confident that this illness affects the central and peripheral nervous system and the interplay with circulation and the delivery of everything in the blood to critical organs. And I think one of the most important areas to me is trying to understand why cellular energy production is abnormal.”
“And so there's now interest all over the world in trying to understand what's going on in long COVID patients. And what we've done in the ME/CFS world is try to keep ME/CFS in the conversation. Always, always, always in the conversation with long COVID and what can we learn and how do we benefit both groups and how do we use what we learn in either field to make it better for everyone.”
“So RECOVER..there's a clinical trials arm of trying to design treatments and test them..And so there have been people with experience in ME/CFS kind of as part of the planning of all of these, trying to be that voice that brings up the relationship between the illnesses. But for example, the whole first protocol for looking at long COVID patients didn't ask appropriately about post-exertional malaise, because people didn't believe it. It's just the people planning the protocol were like non-believers.
But they've had to go back and revise it because of the large number of patients who report post-exertional malaise. And the same with the clinical trials. They started out really with very little understanding of exercise intolerance and post-exertional malaise and the manifestations. And then we've had an opportunity to really educate those planning, those clinical trials for long COVID, what we've learned from ME/CFS and about pacing and about a post-exertional malaise”
“I would say the most interesting and important area, pivotal area is understanding the energy problems in the cell. And what's creating what appears to be mitochondrial dysfunction. To me, that is going to be pivotal in us being able to move forward and design treatments, and also look back to understand how the immune system is contributing, how the virus is contributing.”
“But what's going on, right? That cellular energy is low & that patients just are unable to do very much without becoming very ill. To me, that is going to be the most important area that I'm kind of keeping my eye on, especially as that's coming up in long COVID research as well